Skip to main content
. 2015 Nov 13;1(2):63–73. doi: 10.1002/cre2.11

Figure 2.

Figure 2

Changes in serum levels of IL‐6, sIL‐6R, and sgp130 after TCZ therapy. The “*” denotes that p‐value marks significance of difference between baseline and reassessment (3 and 6 months), as assessed by Friedman and Wilcoxon signed rank tests (p < 0.017). IL‐6, interleukin‐6; sIL‐6R, soluble IL‐6 receptor; sgp130, soluble glycoprotein 130; TCZ, tocilizumab; NS, no significant difference.